A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive
FDA has insisted that its antique regulations can address every new promotional challenge
The more clarity that FDA provides, the more confident companies can be in their medical communications
We need for pharmaceutical companies to come forward and make the pledge to stop hiding data
FDA's Warning Letter to Aegerion is a bureaucratic thumb in the eye to the US Court of Appeals
It's fast becoming an n of 1 world, where every disease is an orphan disease and success is measured by individual outcomes
Keeping up with quality programs often feels like a safari in a jungle of government paperwork
Could PAG change the FDA inspection paradigm from honest, objective assessments to faster, easier ones?
By opposing making clinical trial data public, Pharma is once again swimming against the current
CMS recognized that the rules in place for CME provide for separation from supporter influence
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.